Navigation Links
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
Date:2/12/2009

ransplantation centers in the US and France. Although orBec(R) did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec(R) did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec(R) at 200 days post-transplant with only 5 patient (8%) deaths in the orBec(R) group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139). At one year post randomization in the pivotal Phase 3 trial, 18 patients (29%) in the orBec(R) group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, hazard ratio 0.54, 95% CI: 0.30, 0.99, p=0.04, stratified log-rank test).

In the Phase 2 study, the primary endpoint was the clinically relevant determination of whether GI GVHD patients at Day 30 (the end of treatment) had a durable GVHD treatment response as measured by whether or not they were able to consume at least 70% of their estimated caloric requirement. The GVHD treatment response at Day 30 was 22 of 31 (71%) vs. 12 of 29 (41%) in the orBec(R) and placebo groups, respectively (p-value 0.02). Additionally, the GVHD treatment response at Day 40 (10 days post cessation of therapy) was 16 of 31 (52%) vs. 5 of 29 (17%) in the orBec(R) and placebo groups, respectively (p-value 0.007).

orBec(R) represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where GVHD is most frequently encountered and highly problematic. orBec(R) is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD. Beclomethasone
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
2. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
3. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
4. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
6. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
7. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
8. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
9. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
10. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 ... solution for this disorder in a new review published ... difficult condition to deal with, so there is no ... to overcome it. The Natural Vitiligo Treatment is one ... , The Natural Vitiligo Treatment promises to stop the ...
(Date:8/30/2014)... August 30, 2014 The Plastic Surgery ... New Jersey and even in the U.S. to provide ... inches off of patients’ waists with deep-tissue heating. , ... small sections, Vanquish is more inclusive to target large ... lay comfortably under panels about one inch away from ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, has ... Dementia, and Memory Loss . , Country singer Glen Campbell, ... the Alzheimer’s, inspired Seniors Guide writers to review the trailer ... out on October 14, 2014, shows a glimpse of Glen ... – which inspires a final tour from the musician while ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... five patients operated on for broken bones or other orthopedic ... study finds. Less-educated patients and patients who had ... be "doctor shoppers," said study lead author Dr. Brent Morris, ... said, the study suggests that doctors aren,t talking to one ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... (Pink Sheets: BPYT) ("Bioponic"), an innovative provider of ... (CAM) and nutraceutical markets, announced today that it ... Financial,Communications Corporation, as its investor relations representative. ... and approximately 62% of U.S.,adults are using some ...
... disease, study finds , , THURSDAY, Oct. 4 (HealthDay News) -- ... the heart,s left main artery should take special care of ... sisters of someone with such problems are 2.5 times more ... the siblings of patients with heart disease not related to ...
... ROCKVILLE, Md., Oct. 4 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases,announced today ... Officer,will present a Company overview at the Biotechnology ... Palace Hotel, San Francisco,California, October 9-11, 2007. Mr. ...
... Oct. 4 According to the,November 2006 Rand ... alone costs about $6.4 billion a year nationally ... If another amnesty were adopted,tens of millions of ... be added within 20 years to the U.S. ...
... The National Confectioner,s,Association has noted that up to ... this in mind, Halloween is a perfect time ... children. "Since candy and Halloween go together...Consider ... can enjoy chocolate and,lollipops on occasion as long ...
... following is a,statement by Michael Bender, director of The ... Food and Drug Administration and its various,expert groups, and ... years to present a balanced and clear message in ... there is,there is enough mercury in certain fish to ...
Cached Medicine News:Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 3Health News:Cardiac Artery Trouble Boosts Family Heart Risk 2Health News:Cardiac Artery Trouble Boosts Family Heart Risk 3Health News:EntreMed to Present at the Bio 2007 Investor Forum 2Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2
(Date:8/29/2014)... Ohio , Aug. 29, 2014  In ... how to leverage a hospital pharmacy as a strategic ... and national practice leader for Cardinal Health,s Innovation Delivery ... pharmacy care can benefit both hospitals and patients. ... is only one part of their job in a ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 ... DMPI) ("DelMar" "the Company") today announced the filing of ... recently changed its fiscal year end to June 30th ... common stock on a national securities exchange in the ... filed with the United States Securities Exchange Commission can ...
(Date:8/29/2014)... -- , Industry professionals and media ... taking place in real-time at CPhI Worldwide  ... UBM Live , announces the launch of #CPhIChat ... its kind global industry-wide Tweetchat for pharma professionals ... to stimulate conversations on key industry issues and ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3
... Jan. 25, 2012  Amorcyte, LLC, a NeoStem, Inc. ... announces the enrollment of the first patient in ... myocardial infarction. The study is a multicenter, randomized, ... and efficacy of infarct-related artery infusion of AMR-001, ...
... hosting a free webinar on the upcoming changes to the ... and is intended to address the growing number of questions ... (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ) "We,ll do ... the current status and upcoming changes, as well as insight ...
Cached Medicine Technology:Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
World's first commercially available vacuum assisted biopsy device for MRI....
... Now you can perform stereotactic, ultrasound and ... convenience of your office. Use the patented, ... easier and more clinically advanced method of ... best for the women who trust YOU.,12 ...
... perform stereotactic, ultrasound and MRI-guided vacuum assisted ... office. Use the patented, FDA-cleared ATEC system ... clinically advanced method of breast biopsy. Its ... women who trust YOU.,9 Gauge Handpieces: Useful ...
36" Penrose drains...
Medicine Products: